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Dr Tsilpanilis1 has proposed an interesting hypothesis that
a low fat mass may play a causative role in poor survival by
inducing enhanced inflammatory responses. Although this
possibility was not discussed in our recent paper,2
describing the inverse association between fat mass and
mortality risk in hemodialysis patients, it may be another
explanation for the reverse epidemiology in the dialysis
population.
It is important to note that most of studies reporting
the reverse epidemiology were based on data of mortality,
not occurrence of cardiovascular event, for example, as an
end point. These studies are reporting that obese dialysis
patients have a lower risk of death, but they are not saying
that obese dialysis patients have a lower possibility to have
cardiovascular events. According to the data from Japanese
Society for Dialysis Therapy,3 the risk of death from
myocardial infarction or heart failure was inversely
associated with body mass index in 39 725 non-diabetic
hemodialysis patients. In contrast, the risk of occurrence of
new myocardial infarction had no significant association
with body mass index in the same report,4 suggesting
that a higher body mass index is protective against
death after getting heart disease. Thus, it is clear that the
risk of death consists of two components, namely the risk
of event occurrence and the risk of death following the
event (fatality).5 As we previously discussed,6 hemodialysis
patients have several times higher risk of occurrence of
cardiovascular events than the general population, and
several times higher risk of fatality after getting a
cardiovascular event. The product of these two compo-
nents explains the 10–30 times higher risk of death due to
cardiovascular disease in the hemodialysis population.7
The reverse epidemiology among hemodialysis patients
gives us many hints to understand the real problems they
have. We speculate that wasting associated with chronic
inflammation in uremia plays an important role in the
elevated risk of fatality. To improve their outcomes, further
studies are needed to test individual hypotheses in
observational and interventional settings.
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Urotensin in ESRD: Not so
surprising
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To the Editor: We read with interest the nice review on
urotensin (UTN) by Dr N Ashton.1 While commenting on
papers by our group, reporting (unexpected) inverse relation-
ships of UTN with brain natriuretic peptide (BNP),
sympathetic activity, and other biomarkers of cardiovascular
risk and with incident cardiovascular events, Dr N Ashton1
says that ‘y possible explanation for this apparent ano-
maly is y that the relationship between plasma UII and
cardiovascular events is disease-specific’. We believe that this
explanation is unlikely because, evidence is emerging that in
coronary syndromes (i.e. a condition where high UTN has
long been considered as a marker of high cardiovascular risk)
low rather than high UTN predicts adverse outcomes.2,3
Furthermore, still unpublished results by our group show
that UTN is inversely related with left ventricular mass and
mean wall thickness (the muscular component of the left
ventricular) in the end-stage renal disease population. These
findings are again apparently counterintuitive when com-
pared with studies in the rat or in ‘in vitro’ models, showing
that UTN causes myocardial cell hypertrophy and myocardial
fibrosis.4 We feel that interpreting UTN as a ‘bad guy’ in
human pathophysiology and extrapolating results of animal
models to humans is a risky exercise at this stage of
knowledge. We do fully agree with the concluding comments
of the editorial ‘ywhethery (urotensin)y role is protec-
tive or causal remains to be determined’. Studies in humans
based on specific antagonists of this most intriguing peptide
are needed to understand whether UTN is noxious or
protective in man.
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